Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 141
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: IRFMN-MPM-6077|2011-006330-16
Study First Received: July 16, 2014
Last Updated: August 30, 2016
Estimated Primary Completion Date: October 2016
Primary Outcome Measures:
Progression Free Survival – PFS12w|Progression Free Survival (PFS)|Overall survival (OS)|Objective response rate|Trabectedin tolerability and safety|Pain Intensity (PI)|Pain type and characteristics|Antalgic treatments|microRNA (miRs) profile|High Mobility Group B1 (HMGB1) protein assessment|Blood Macrophages analysis
Sponsors and Collaborators:
Mario Negri Institute for Pharmacological Research|PharmaMar
Website Link: https://ClinicalTrials.gov/show/NCT02194231
